Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
Eledon presented new positive patient-reported outcomes from the Phase 2 BESTOW trial at ASN Kidney Week 2026, showing sustained quality-of-life and symptom-burden improvements with tegoprubart versus tacrolimus through 12 months post kidney transplant. Tegoprubart patients improved 9.0 points on the KDQOL-SF Symptoms and Problems Scale versus 3.3 for tacrolimus (p<0.05), with greater symptom improvement in 22 of 23 differential domains; tegoprubart patients improved while tacrolimus patients worsened on the total MTSOSD-59R at Month 12.
Key figures
- Drug Name
- tegoprubart
- Phase Of Trial
- Phase 2
- Sf12 between group difference
- 3.1
- Sf12 mental component change tegoprubart
- 1.5
- Kdqol sf symptoms problems change tacrolimus
- 3.3
- Kdqol sf symptoms problems change tegoprubart
- 9
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.